Author name: KM

The Potential of Lipid Nanoparticles in mRNA Vaccine Delivery In recent years, researchers have been actively exploring new treatment modalities for infectious diseases, with a particular focus on the development of nanomedicine. Nanomedicine involves the use of nanoscale materials to diagnose and treat diseases, including the targeted delivery of drugs to specific locations within the […]

European Medicines Agency’s Report for 2022: Protecting and Strengthening Public Health in the European Union The European Medicines Agency (EMA) (official web-site) published its report for the year 2022. The report provides an overview of the measures taken to protect and strengthen public health in the European Union (EU). The EMA recommended the approval of

A recent study published in Vaccines found that almost half of patients with autoimmune inflammatory rheumatic diseases (AIIRD) were vaccinated against pneumococcal infection, while more than two-thirds were vaccinated against influenza. These rates suggest an improvement in recent years, although vaccination rates for these viruses remain low in this patient population, who are at higher

Researchers published a study in PNAS which found that a promising breakthrough in the elimination of human immunodeficiency virus type 1 (HIV-1) in humanized and infected mice was achieved by combining two CRISPR gene editing therapies with antiretroviral therapy (ART). This revolutionary treatment approach has the potential to transform the management of HIV-1 in humans.

Fatigue is a common symptom experienced by nearly 50% of individuals with Parkinson’s disease, and can be debilitating and persistent, often unrelieved by rest. While fatigue can be a subjective experience, it is important for clinicians to understand potential underlying causes in order to provide appropriate management. Here, we highlight five common causes of fatigue

A study published in Neurology  suggests that receiving a flu vaccine may reduce the risk of stroke. Researchers analyzed a health care database of nearly 3 million people in Spain over a 14-year period and identified 14,322 individuals who were at least 40 years old and had experienced an ischemic stroke, as well as 71,610

Gilead Sciences, Inc. (Nasdaq: GILD) has reported positive findings from several studies related to COVID-19, which will be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). One Phase 3 clinical trial showed that Veklury® (remdesivir) was well tolerated by patients with moderate to severe renal impairment. In addition, a retrospective

A systematic review published in Circulation: Cardiovascular Quality and Outcomes found that participating in an intensive behavioral weight loss program and making lifestyle changes can lead to a decrease in risk factors for cardiovascular disease (CVD) and type 2 diabetes (T2D) for at least 5 years, even if the weight is regained. According to Susan

A recent study conducted by experts from the Johns Hopkins University School of Medicine has found that patients living with HIV may experience worsened cognitive function during the first four months after being infected with SARS-CoV-2. However, the study suggests that these differences in cognitive function are likely attributable to HIV rather than COVID-19. The